IQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance

Revenue for the fourth quarter of $2,161 million increased 10.7 percent on a reported basis ... which was divested in July 2017. Research & Development Solutions revenue of $3,647 million for the full year of 2017 grew 4.3 percent reported and 4.4 percent ...

Jamba, Inc. Provides Update for Fourth Quarter and Fiscal Year 2017, Select Business Initiatives and Issues Initial 2018 Guidance

As of January 2, 2018, the Company held $10.0 million in cash, as compared to $7.1 million at January 3 ... of its Forms 10-Q for the fiscal quarters ended April 4, July 4 and October 3, 2017 on or before March 15, 2018. The Company is diligently working ...

BRIEF-Pluristem Therapeutics says on July 7, co entered into an at market issuance sales agreement - SEC Filing

Pluristem Therapeutics Inc - On July 7, 2017, co entered into an at market issuance sales agreement - SEC Filing * Pluristem Therapeutics Inc - Pluristem may issue and sell shares of common stock having aggregate offering price of up to $80 million from ...